Purchase Order 75F40124P00124

Award Date 5/8/24
Potential Completion Date 6/8/25
Potential Value $27K
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Madison, WI 53711, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award from the Food and Drug Administration (FDA) to Fujifilm Cellular Dynamics, Inc., a foreign-owned for-profit manufacturer, is for the provision of human induced pluripotent stem derived cardiomyocytes. The $84,500.00 firm-fixed-price purchase order contract has a period of performance through March 20, 2017. The contract is not set aside for small businesses. Fujifilm Cellular Dynamics is a key supplier of specialized and proprietary human cell lines, including diverse...
This is a firm-fixed-price purchase order contract awarded by the Food and Drug Administration (FDA), a civilian agency within the U.S. Department of Health and Human Services, to Fujifilm Cellular Dynamics, Inc., a foreign-owned, for-profit manufacturer of biologically relevant human cells derived from induced pluripotent stem cells (iPSCs). The contract has a ceiling value of $119,350.00 and is not set aside for small businesses. The contract is for the supply of "MYCELL AND ICELL...
This is a $99,500.00 firm-fixed-price purchase order contract awarded by the Food and Drug Administration (FDA), a civilian agency within the U.S. Department of Health and Human Services, to Fujifilm Cellular Dynamics, Inc., a foreign-owned, for-profit manufacturer of induced pluripotent stem cell-derived human cell lines. The contract is for the supply of iCell Cardiomyocytes, a specialized cell product used in biomedical research, drug development, and toxicology screening. The contract has...
This is a firm-fixed-price purchase order contract awarded by the Food and Drug Administration (FDA) to Fujifilm Cellular Dynamics, Inc., a foreign-owned, for-profit manufacturer of induced pluripotent stem cell-derived human cell lines. The $11,940 contract is for the supply of cardiomyocytes (heart muscle cells) and does not have a small business set-aside designation. Fujifilm Cellular Dynamics has been a consistent provider of specialized cell products to various federal agencies,...
This is a firm-fixed-price purchase order awarded by the Food and Drug Administration (FDA), a civilian agency within the Department of Health and Human Services, to Fujifilm Cellular Dynamics, Inc., a foreign-owned, for-profit manufacturer of induced pluripotent stem cell (iPSC)-derived human cell lines. The $79,500.00 contract is for the supply of human iPSC-derived cardiomyocytes (heart muscle cells) to support biomedical research, drug development, and toxicology screening initiatives. The...
This is a $124,070 firm fixed-price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency under the U.S. Department of Health and Human Services, to Fujifilm Cellular Dynamics, Inc., a foreign-owned, for-profit manufacturer of induced pluripotent stem cell (iPSC) derived human cell products. The contract is for the delivery of iPSC-derived human neurons and astrocytes, which are biologically relevant cell types used to support biomedical...
This is a $23,906 firm fixed price purchase order awarded to Fujifilm Cellular Dynamics, Inc., a foreign-owned, for-profit manufacturer of biologically relevant human cells derived from induced pluripotent stem cells (iPSCs). The award is from the National Center for Advancing Translational Sciences (NCATS), which is part of the National Institutes of Health (NIH) within the Department of Health and Human Services. The contract is for the delivery of various iPSC-derived cell types, such as...
The U.S. Food and Drug Administration (FDA) awarded a $98,725.00 firm fixed-price purchase order to Fujifilm Cellular Dynamics, Inc. (FCDI), a foreign-owned, for-profit manufacturer of biologically relevant human cells derived from induced pluripotent stem cells (iPSCs). The contract is for the purchase of cardiomyocytes, which are heart muscle cells, and does not have a set-aside designation. FCDI is a key supplier of specialized cell products, particularly to the Department of Health and Human...
This federal contract award, valued at $23,850.00, was issued by the Food and Drug Administration (FDA) to Fujifilm Cellular Dynamics, Inc., a foreign-owned, for-profit manufacturer of biologically relevant human cells derived from induced pluripotent stem cells (iPSCs). The contract is designated as a Total Small Business set-aside and is for the delivery of CARDIOMYOCYTES, which are specialized cardiac muscle cells. Fujifilm Cellular Dynamics has a strong track record of supplying diverse...
This contract award to Fujifilm Cellular Dynamics, Inc. (FCDI) is for the provision of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) to the Food and Drug Administration (FDA). The $42,995 firm-fixed-price purchase order has a period of performance through December 31, 2024. FCDI is a foreign-owned, for-profit manufacturer of specialized human cell cultures, particularly those derived from induced pluripotent stem cells (iPSCs). The company has an extensive history of...

This is a firm-fixed-price purchase order awarded by the Department of Health and Human Services Food and Drug Administration to Fujifilm Cellular Dynamics, Inc., a foreign-owned, for-profit manufacturer of human induced pluripotent stem cell-derived cells. The $26,680 contract is to provide specialized cell cultures, including cardiomyocytes, neurons, astrocytes, and hepatocytes, to support the FDA's active research program. The award has no set-aside designation and is a sole-source award, as Fujifilm Cellular Dynamics is the only known vendor capable of providing the required proprietary cell lines and differentiation processes validated by the FDA. The contract has a completion date of June 8, 2025.

Generated 5/9/24, 11:10 AM